Dongcheng Pharmaceutical announced that the 22nd meeting of the sixth board of directors of the company deliberated and passed four proposals: one is to terminate the spin-off of its subsidiary and listing on the main board of the Hong Kong Stock Exchange; the second is to buy minority shareholders' shares and related transactions. The relevant directors are to be voted out by the shareholders' meeting. The third is to change the company's business scope and revise the “Articles of Association”. The bill needs to be submitted to the shareholders' meeting for consideration; fourth, to request the holding of the second extraordinary shareholders' meeting in 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.